Prescribing Information | Safety Information | References

New extended-release technology

CARDURA XL utilizes a patent-protected delivery system for an extended release of doxazosin

Chart

Benefits for your BPH patients

Gradual and steady plasma levels, especially at onset ^1,2
In clinical trails, the final daily dose of CARDURA XL was 4 mg in 43% of patients and 8mg in 57% of patients ¹
Flexible dosing from 4 to 8 mg ^1-4

* Immediate release

next section »		Efficacy

Important Safety Information

CARDURA XL is contraindicated in patients with a known sensitivity to other quinazolines (eg, prazosin, terazosin), doxazosin, or any of the inert ingredients. Postural hypotension with or without symptoms (eg, dizziness) may develop within a few hours following administration of CARDURA XL. However, infrequently, symptomatic postural hypotension has also been reported later than a few hours after dosing.

Caution should be used when administering CARDURA XL to patients with preexisting severe gastrointestinal tract narrowing, chronic constipation, or evidence of hepatic dysfunction.

The most commonly reported adverse events were: headache, dizziness, respiratory tract infection, asthenia, and back pain.

CA266876